Autopsy report · NCT02082197

An Efficacy and Safety Study of ABT-SLV176 for the Treatment of Hypogonadal Men

“Other - not a safety issue”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

AbbVie

Sponsor type

Industry

Conditions

Hypogonadism; Testosterone Deficiency

Interventions

ABT-SLV176

Participants

0

Sites

42

Countries

United States

Trials that died the same way

• A Phase I Trial of a LTK63 Adjuvated Tuberculosis Nasal Subunit Vaccine (Ag85B-ESAT6)
  “Safety Issues” (70% match in meaning)
• Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring (TDF IVR-002)
  “Safety-related” (65% match in meaning)
• Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
  “Business reasons and not due to any safety concerns” (63% match in meaning)
• AGN-242428 in the Treatment of Plaque Psoriasis
  “safety reason” (61% match in meaning)
• Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)
  “Business reasons not related to safety” (60% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.